Objective To understand the change in antimicrobial resistance of Granulicatella adiacens (G. adiacens) clinically isolated from blood specimens in China, provide basis for clinical treatment. Methods Surveillance on antimicrobial resistance of bacteria was carried out according to the requirements of China Antimicrobial Resistance Surveillance System (CARSS). Antimicrobial susceptibility testing results of G. adiacens isolated from blood specimens of member units of CARSS in 2014-2021 were analyzed based on standard of American Clinical and Laboratory Standards Institute (CLSI). Results 83-152 strains of G. adiacens were isolated from blood specimens from member units of CARSS each year from 2014 to 2021, there was a gradual increasing trend after 2017. The susceptibility rates of G. adiacens isolated from blood specimens to vancomycin and meropenem were 100% and 93.7% respectively, to ceftriaxone, cefotaxime and cefepime were about 90%, to levofloxacin, penicillin, erythromycin and clindamycin were 82.8%, 65.0%, 32.7% and 46.8%, respectively. From 2014 to 2021, susceptibility rates of G. adiacens to partial antimicrobial agents increased to varying degrees, but to cefepime and meropenem decreased. Conclusion The number of G. adiacens isolated from blood specimens showed a rising trend, G. adiacens exhibits varying degrees of resistance to penicillin, cephalosporins, carbapenems, fluoroquinolones and macrolides, but no vancomycin-resistant strain was found.